CL2021000592A1 - Método para producir un arenavirus antitumoral así como mutantes de arenavirus - Google Patents

Método para producir un arenavirus antitumoral así como mutantes de arenavirus

Info

Publication number
CL2021000592A1
CL2021000592A1 CL2021000592A CL2021000592A CL2021000592A1 CL 2021000592 A1 CL2021000592 A1 CL 2021000592A1 CL 2021000592 A CL2021000592 A CL 2021000592A CL 2021000592 A CL2021000592 A CL 2021000592A CL 2021000592 A1 CL2021000592 A1 CL 2021000592A1
Authority
CL
Chile
Prior art keywords
arenavirus
antitumor
mutants
produce
well
Prior art date
Application number
CL2021000592A
Other languages
English (en)
Inventor
Karl Lang
Cornelia Hardt
Michael Bergerhausen
Hilal Bhat
Original Assignee
Abalos Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abalos Therapeutics Gmbh filed Critical Abalos Therapeutics Gmbh
Publication of CL2021000592A1 publication Critical patent/CL2021000592A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • C12N2760/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere a un mutante de un arenavirus que tiene propiedades antitumorales mejoradas. La invención también se refiere a un método para generar este mutante de arenavirus, composiciones farmacéuticas relacionadas, usos médicos, métodos de tratamiento, y proteínas aisladas y ácidos nucleicos.
CL2021000592A 2018-09-12 2021-03-10 Método para producir un arenavirus antitumoral así como mutantes de arenavirus CL2021000592A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102018215551.8A DE102018215551A1 (de) 2018-09-12 2018-09-12 Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten

Publications (1)

Publication Number Publication Date
CL2021000592A1 true CL2021000592A1 (es) 2021-09-10

Family

ID=68138008

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000592A CL2021000592A1 (es) 2018-09-12 2021-03-10 Método para producir un arenavirus antitumoral así como mutantes de arenavirus

Country Status (18)

Country Link
US (1) US20220033445A1 (es)
EP (2) EP3694868B1 (es)
JP (1) JP2022500054A (es)
KR (1) KR20210057782A (es)
CN (1) CN112996802A (es)
AU (1) AU2019340845A1 (es)
BR (1) BR112021004451A2 (es)
CA (1) CA3111305A1 (es)
CL (1) CL2021000592A1 (es)
DE (1) DE102018215551A1 (es)
DK (1) DK3694868T3 (es)
ES (1) ES2908854T3 (es)
IL (1) IL281299A (es)
MX (1) MX2021002937A (es)
PH (1) PH12021550424A1 (es)
SG (1) SG11202101970UA (es)
WO (1) WO2020053324A1 (es)
ZA (1) ZA202101833B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL305349A (en) 2021-02-26 2023-10-01 Abalos Therapeutics Gmbh New virus particles for medical purposes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004034461B4 (de) * 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
FI2604695T3 (fi) 2007-12-27 2023-02-16 Replikaatiokyvyttömiä arenavirusvektoreita
JP5548207B2 (ja) * 2008-09-24 2014-07-16 メディミューン，エルエルシー ウイルスの精製方法
CN103597098A (zh) * 2011-01-07 2014-02-19 斯洛伐克生物科学公司 病毒诊断
BR112015013669A2 (pt) * 2012-12-12 2017-11-14 Childrens Hospital Of Eastern Ontario Res Institute Inc composições e métodos para o tratamento de cânceres cerebrais
DE102015207036A1 (de) * 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
CA3039356A1 (en) * 2016-11-04 2018-05-11 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines

Also Published As

Publication number Publication date
ES2908854T3 (es) 2022-05-04
CA3111305A1 (en) 2020-03-19
MX2021002937A (es) 2021-07-16
AU2019340845A1 (en) 2021-05-06
SG11202101970UA (en) 2021-03-30
US20220033445A1 (en) 2022-02-03
EP3694868B1 (en) 2021-11-03
EP3694868A1 (en) 2020-08-19
EP4019533A1 (en) 2022-06-29
IL281299A (en) 2021-04-29
BR112021004451A2 (pt) 2021-06-01
PH12021550424A1 (en) 2021-09-20
ZA202101833B (en) 2022-10-26
DK3694868T3 (da) 2022-02-07
KR20210057782A (ko) 2021-05-21
JP2022500054A (ja) 2022-01-04
CN112996802A (zh) 2021-06-18
WO2020053324A1 (en) 2020-03-19
DE102018215551A1 (de) 2020-03-12

Similar Documents

Publication Publication Date Title
CY1124845T1 (el) Μεθοδοι παροχης μονοκλωνου rna
PH12021551065A1 (en) Fused ring compounds
CY1124896T1 (el) Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων
CY1122035T1 (el) Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
BR112016029041A2 (pt) terapia de combinação com inibidores de glutaminase
PH12019502333A1 (en) Targeted compositions
BR112017018975A2 (pt) proteínas de fusão compreendendo uma proteína de ligação e um polipeptídeo de interleucina-15 tendo uma afinidade reduzida com il15ra e usos terapêuticos das mesmas
CL2021002503A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251)
EA201791095A1 (ru) Способ лечения рака
BR112016017041A2 (pt) Proteína isolada tendo atividade de fosfatase, polinucleotídeo, vetor, célula hospedeira, método para produzir uma proteína e composição
EP4257152A3 (en) Apelin polypeptides
BR112016023707A2 (pt) método para produzir l-aminoácidos com o uso de uma bactéria alcalifílica
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
MX2023001877A (es) Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9.
MX2019012144A (es) Arn para tratamiento de enfermedades autoinmunitarias.
AU2018348359A8 (en) Extended release pharmaceutical formulation and methods of treatment
CY1118704T1 (el) Ανθρωπινος πληθυσμος βλαστοκυτταρων του τραχηλου της μητρας και χρησεις αυτου
BR112018014540A2 (pt) formulações/composições compreendendo inibidor de btk
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
BR112018006870A2 (pt) nanopartículas terapêuticas que compreendem um agente terapêutico e métodos para a produção e o uso das mesmas
CL2021000592A1 (es) Método para producir un arenavirus antitumoral así como mutantes de arenavirus
BR112019008606A2 (pt) inibidores de interações de mtor-deptor e métodos de uso dos mesmos
CO2020013557A2 (es) Variantes de lfa3 y composiciones y usos de las mismas
MX2021004581A (es) Composiciones acuosas que comprenden omega nitrooxi-1-alcanoles.